NEW YORK (GenomeWeb News) – Helicos BioSciences has amended a licensing deal with Arizona Technology Enterprise to include the rights to sequencing-based detection methods that do not rely on optically-labeled nucleotides, the Cambridge, Mass.-based firm announced after the close of the market on Tuesday.
The amended agreement now gives Helicos patent rights to several sequencing-by synthesis methods and includes "all activities that fall within the scope of, or constitute the practice of, the licensed patents, and give Helicos full and unencumbered rights to the associated intellectual property," it said.
In 2005 Helicos exclusively licensed certain patent rights and patent applications from ATE, which had previously licensed them from Arizona State University and the University of Alberta.
Under the amended agreement, Helicos remains obligated to pay ATE an undisclosed percentage of income from Helicos-granted sub-licenses or other transfers of the ATE licensed rights, including any sale of the company or settlement of litigation, Helicos said in a document filed with the US Securities and Exchange Commission on Tuesday.
Additional financial terms of the amended licensing deal were not disclosed.
Ivan Trifunovich, president and CEO of Helicos, said in a statement that the "newly acquired rights will be an important asset in our licensing and IP monetization efforts" that also include a lawsuit it has filed against Illumina, Life Technologies, and Pacific Biosciences alleging patent infringement of its single-molecule sequencing technology.
Earlier this month Helicos reported a 22 percent increase in its second-quarter revenues.